Person: COŞKUN, NECMİYE FUNDA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
COŞKUN
First Name
NECMİYE FUNDA
Name
49 results
Search Results
Now showing 1 - 10 of 49
Publication Response to "Hypercapnic respiratory failure with insufficient response to fixed- level PS-NIV: Is AVAPS the end solution?"(Turkish Assoc Tuberculosis & Thorax, 2023-01-01) Öztürk, Nilüfer Aylin Acet; Güçlü, Özge Aydın; Demirdoğen, Ezgi; Dilektaşlı, Aslı Görek; Maharramov, Shahriyar; Coşkun, Funda; Uzaslan, Esra; Ursavaş, Ahmet; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; AYDIN GÜÇLÜ, ÖZGE; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; Maharramov, Shahriyar; COŞKUN, NECMİYE FUNDA; URSAVAŞ, AHMET; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0002-6375-1472; 0000-0003-1005-3205; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0003-3604-8826; 0000-0002-9027-1132; Z-1424-2019; AAG-9930-2019; AAH-9812-2021; DTT-7416-2022; DDT-7334-2022; AAD-1271-2019; CDI-1977-2022; AAG-8744-2021Publication Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting(Tubitak Scientific & Technological Research Council Turkey, 2021-01-01) Cilli, Aykut; Hanta, Ismail; Sevinc, Can; Odemi, Ayse; Coskun, Necmiye Funda; COŞKUN, NECMİYE FUNDA; Ursavas, Ahmet; URSAVAŞ, AHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0003-3604-8826; 0000-0002-4069-9181; AAI-3169-2021; AAD-1271-2019Background/aim: Phase III trials have demonstrated a significant efficacy and an acceptable safety for pirfenidone in patients having mild to moderate idiopathic pulmonary fibrosis (IPF). Real-life data on the use of pirfenidone 200 mg tablets are limited. This study aimed to investigate the efficacy and safety of pirfenidone 200 mg tablets for the treatment of IPF in a real-life setting. Materials and methods: A retrospective, multicenter study conducted in four university hospitals in Turkey between January 2017 and January 2019. Clinical records of patients diagnosed with mild to moderate IPF and receiving pirfenidone (200 mg tablets, total 2400 mg/day) were reviewed retrospectively and consecutively. Pulmonary function measurements including forced vital capacity (FVC%) and diffusing capacity of the lungs for carbon monoxide (DLCO%) were analyzed at baseline and after 6-month of pirfenidone treatment. Descriptive statistics were expressed as mean, standard error or median (minimum-maximum), number and percentage, where appropriate. Results: The study included 82 patients, of whom 87.8% were males (mean age, 66 years). After 6-month of treatment, 7 patients discontinued the treatment. Of the remaining 75 patients, 71 (94.6%) remained stable, 4 (5.4%) had progressive disease as evident by a decline in the FVC% of at least 10% while on treatment, and 45 (61.3%) had improved cough. At least one adverse event (AE) associated with the treatment was observed in 28 (37.3%) patients. Conclusion: Pirfenidone 200 mg was effective and well tolerated and associated with relatively mild and manageable AEs in IPF patients.Publication Factors associated with mortality in cases of idiopathic pulmonary fibrosis with mild to moderate functional impairment(Kare Publ, 2023-09-01) Şengül, Aysun; Özyürek, Berna Akıncı; Coşkun, Funda; Yazıcı, Onur; Bozkuş, Fulsen; Gülhan, Pınar Yıldız; Satıcı, Celal; COŞKUN, NECMİYE FUNDA; Bursa Uludağ Üniversite/Tıp Fakültesi/Göğüs Hastalıklar Anabilim Dalı.; JWQ-2804-2024BACKGROUND AND AIM: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease with a poor prognosis, characterized by advanced fibrosis. The course of the disease varies from patient to patient. The factors that determine the course of the disease are yet to be clarified. Here, we aimed to assess patient characteristics, overall mortality, and mortality -associated factors in our IPF patient cohort. METHODS: Our multicenter, retrospective cohort study reviewed the records of 169 patients diagnosed with IPF who had mild-to-moderate functional impairment and were followed up for at least one year from diagnosis until death between 2009 and 2019. RESULTS: The mean age of the 169 IPF patients was 69.7 +/- 8.8 years, and 73.4% were male. The diagnosis was established clinically and radiologically in 152 (89.9%) patients and histopathologically in 17 (10%) patients. A smoking history was found in 72.2% of the patients, with an average smoking quantity of 35.6 +/- 14.7 pack-years. Among the patients, 28 (16.6%) did not receive treatment, 87 (51.5%) received pirfenidone, and 54 (31.9%) nintedanib treatment. The median Gender, Age, and Physiology (GAP) score of the patients was 3. The mean forced vital capacity (FVC) was 79.6%+/- 19.7%, the mean diffusing capacity of the lungs for carbon monoxide (DLCO) was 52.8%+/- 14.5%, the median pulmonary hypertension score was 2, the mean pulmonary artery to-aorta (PA/Aorta) ratio was 0.85 +/- 0.15, the mean arterial partial pressure of oxygen (PaO2) was 66 +/- 10.7 mmHg, and the median right ventricular systolic pressure (RVSP) was 30 (range: 19-60) mmHg. The one-year mortality rate was 7.1%, the two-year mortality rate was 19.6%, and the three-year mortality rate was 42.5%. The factors associated with one-and two-year mortality were age, GAP score, RVSP, and non-treatment. The factors associated with three-year mortality were age, GAP score, non-treatment, and the PA/Aorta ratio. CONCLUSIONS: Antifibrotic therapy improves disease prognosis and can reduce mortality in patients diagnosed with IPF. Elevation of RVSP on echocardiography and PA/Aorta ratio on thoracic computed tomography can be used as predictors of mortality, similar to the GAP score.Publication Development and validation of a simple risk scoring system for a COVİD-19 diagnostic prediction model(Tüberküloz ve Toraks, 2023-01-01) Güçlü, Özge Aydın; Ursavaş, Ahmet; Ocakoğlu, Gokhan; Demirdogen, Ezgi; Öztürk, Nilufer Aylin Acet; Topçu, Dilara Ömer; Terzi, Orkun Eray; Onal, Uğur; Dilektaşlı, Aslı Görek; Sağlık, İmran; Coşkun, Funda; Ediger, Dane; Uzaslan, Esra; AkalIn, Halis; Karadağ, Mehmet; AYDIN GÜÇLÜ, ÖZGE; URSAVAŞ, AHMET; OCAKOĞLU, GÖKHAN; DEMİRDÖĞEN, EZGİ; ACET ÖZTÜRK, NİLÜFER AYLİN; ÖMER TOPÇU, DİLARA; TERZİ, ORKUN ERAY; ÖNAL, UĞUR; GÖREK DİLEKTAŞLI, ASLI; SAĞLIK, İMRAN; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; UZASLAN, AYŞE ESRA; AkalIn, Halis; KARADAĞ, MEHMET; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı; 0000-0003-1005-3205; 0000-0002-1114-6051; 0000-0002-7400-9089; 0000-0002-6375-1472; 0000-0001-7099-9647; 0000-0002-2954-4293; 0000-0001-7530-1279; 0000-0002-9027-1132; AAH-5180-2021; A-4970-2019; AAG-8744-2021; AAI-3169-2021; JCO-3678-2023; JPK-7012-2023Introduction: In a resource-constrained situation, a clinical risk stratification system can assist in identifying individuals who are at higher risk and should be tested for COVID-19. This study aims to find a predictive scoring model to estimate the COVID-19 diagnosis.Materials and Methods: Patients who applied to the emergency pandemic clinic between April 2020 and March 2021 were enrolled in this retrospective study. At admission, demographic characteristics, symptoms, comorbid diseases, chest computed tomography (CT), and laboratory findings were all recorded. Development and validation datasets were created. The scoring system was performed using the coefficients of the odds ratios obtained from the multivariable logistic regression analysis.Results: Among 1187 patients admitted to the hospital, the median age was 58 years old (22-96), and 52.7% were male. In a multivariable analysis, typical radiological findings (OR= 8.47, CI= 5.48-13.10, p< 0.001) and dyspnea (OR= 2.85, CI= 1.71-4.74, p< 0.001) were found to be the two important risk factors for COVID-19 diagnosis, followed by myalgia (OR= 1.80, CI= 1.082.99, p= 0.023), cough (OR= 1.65, CI= 1.16-2.26, p= 0.006) and fatigue symptoms (OR= 1.57, CI= 1.06-2.30, p= 0.023). In our scoring system, dyspnea was scored as 2 points, cough as 1 point, fatigue as 1 point, myalgia as 1 point, and typical radiological findings were scored as 5 points. This scoring system had a sensitivity of 71% and a specificity of 76.3% for a cut-off value of >2, with a total score of 10 (p< 0.001).Conclusion: The predictive scoring system could accurately predict the diagnosis of COVID-19 infection, which gave clinicians a theoretical basis for devising immediate treatment options. An evaluation of the predictivePublication Does concomitant extrapulmonary involvement changes characteristic features of pulmonary sarcoidosis?(European Respiratory Soc Journals Ltd, 2013-09-01) Uzaslan, Esra; ACET ÖZTÜRK, NİLÜFER AYLİN; GÖREK DİLEKTAŞLI, ASLI; UZASLAN, AYŞE ESRA; Dilektaslı, Aslı Görek; Çetinoğlu, Ezgi Demirdöğen; Acet, Nilüfer Aylin; Coşkun, Funda; COŞKUN, NECMİYE FUNDA; URSAVAŞ, AHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim; 0000-0001-7099-9647; 0000-0002-7400-9089; 0000-0002-6375-1472; 0000-0003-3604-8826; AAD-1271-2019; Z-1424-2019; AAI-1004-2021; JPK-7012-2023; AAI-3169-2021Publication Diagnostic value of cervical mediastinoscopy: Report of 506 cases(European Respiratory, 2013-09-01) Erol, Mehmet; Melek, Hüseyin; Bayram, Ahmet; Kermenli, Tayfun; Coşkun, Funda; Akyıldız, Elif; Gebitekin, Cengiz; Erol, Mehmet; MELEK, HÜSEYİN; BAYRAM, AHMET SAMİ; Kermenli, Tayfun; COŞKUN, NECMİYE FUNDA; AKYILDIZ, ELİF ÜLKER; GEBİTEKİN, CENGİZ; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Kliniği; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Bölümü; Uludağ Üniversitesi/Tıp Fakültesi/Patholoji Bölümü; 0000-0003-0684-0900; 0000-0002-7371-4026; 0000-0003-3604-8826; AAE-1069-2022; AAD-1271-2019; AAI-5039-2021; JCE-0097-2023; ABB-7580-2020; KHO-7454-2024; A-6612-2019; IAV-7890-2023Publication The relationship between serum periostin levels, 6-minute walking test and quality of life in patients with idiopathic pulmonary fibrosis(Carbone Editore, 2019-01-01) Eken, Özge Aslantekin; ASLANTEKİN EKEN, ÖZGE; Coşkun, Funda; COŞKUN, NECMİYE FUNDA; Demirdöğen, Ezgi; DEMİRDÖĞEN, EZGİ; Dilektaşlı, Aslı Görek; GÖREK DİLEKTAŞLI, ASLI; Ursavaş, Ahmet; URSAVAŞ, AHMET; Budak, Ferah; BUDAK, FERAH; Karadağ, Mehmet; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmunoloji Anabilim Dalı.; 0000-0003-3604-8826; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0001-7625-9148; 0000-0002-9027-1132; AAG-8744-2021; AAI-3169-2021; JPK-7012-2023; AAD-1271-2019; IZP-9398-2023; F-4657-2014; AAH-9812-2021Introduction: Interstitial lung disease (ILD) is a group of chronic respiratory diseases characterized by inflammation and fi-brosis in different patterns at the interstitium, which is the most common form of idiopathic pulmonary fibrosis (IPF). Considering the prevalence, incidence, and outcomes of IPF, it is important to ensure the availability and validity of biomarkers that can be used in determining the diagnosis and prognosis. In this study, we aimed to assess the relationship between serum periostin levels, pulmonary function tests, 6-minute walking test (6MWT) and quality of life in IPF patients.Material and methods: Our study was carried out with 40 IPF patients who were followed at Uludag University, Faculty of Medicine, Department of Pulmonary Medicine. Spirometer and carbon monoxide diffusion test (DLCO) for respiratory functions, 6MWT and periostin level measurement were performed on the patients, and results were recorded.Results: A total of 31 of patients were males and nine were females. The diagnosis of IPF was made according to the guidelines of ATS / ERS / JRS / ALAT with 25 (62.5%) patients by radiologically and 15 (37.5%) patients with histopathological and radiological features. The mean periostin level was 32.9 +/- 37.57 ng/ml. No significant correlation was found between St. George's Respiratory Questionnaire (SGRQ) score, FVC% predicted, DLCO adj% predicted values, 6MWT distance and periostin level which were measured simultaneously. A negative correlation was found between SGRQ score and DLCO adj% predicted value, 6MWT distance.Conclusion: It has been shown that there is no correlation between periostin levels and the results of the pulmonary function tests, when measured and performed at the same time. No studies are evaluating the relationship between 6MWT and SGRQ scores and periostin levels. In our study, serum periostin level, pulmonary function test results, 6MWT and SGRQ scores were not significantly correlated.Publication Pathophysiologic changes observed during exercise in pulmonary disorders(Aves, 2012-01-01) Coşkun, Funda; COŞKUN, NECMİYE FUNDA; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı; 0000-0003-3604-8826; AAD-1271-2019Chronic pulmonary disease is common in the community and increasing in prevalence. Although numerous etiologies exist, chronic obstructive pulmonary disease (COPD) is mainly secondary to tobacco smoking. The detrimental outcomes of these diseases in patients is disabling breathlessness and impairment of functional exercise capacity. The symptoms set up a vicious cycle leading to physical deconditioning and worsening exercise performance. The pathophysiological hallmark of COPD is expiratory flow limitation. When ventilation increases in flow-limited patients during exercise, air trapping is inevitable and causes further dynamic lung hyperinflation (DH) above the already increased resting volumes. Interstitial lung disease (ILD) causes alveolar and capillary destruction which decreases compliance, increases work of breathing, increases pulmonary vascular resistance, and limits venous return.Publication Evaluation of fibrinogen levels in patients with obstructive sleep apnea syndrome(Wiley, 2013-11-01) Çetinoğlu, Ezgi Demirdoğen; Ursavaş, Ahmet; Karadağ, Mehmet; Coşkun, Funda; Ediger, Dane; Uzaslan, Esra; Ege, Ercüment; Gözü, Oktay; Çetinoğlu, Ezgi Demirdoğen; URSAVAŞ, AHMET; KARADAĞ, MEHMET; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; UZASLAN, AYŞE ESRA; Ege, Ercüment; Gözü, Oktay; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0002-7400-9089; 0000-0002-9027-1132; 0000-0003-3604-8826; 0000-0002-2954-4293; AAI-3169-2021; AAD-1271-2019; AAG-8744-2021; JPK-7012-2023; AAE-9142-2019; AAH-9812-2021; CDI-1977-2022; CPF-5844-2022; JLC-5863-2023Publication Smoking habits of the teachers and their opinion about the new law(Wolters Kluwer Medknow Publications, 2010-12-01) Coşkun, Funda; Karadağ, Mehmet; Ursavaş, Ahmet; Ege, Ercüment; COŞKUN, NECMİYE FUNDA; KARADAĞ, MEHMET; URSAVAŞ, AHMET; Ege, Ercüment; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı; 0000-0003-3604-8826; 0000-0002-9027-1132; AAG-8744-2021; AAD-1271-2019; AAI-3169-2021; CPF-5844-2022Aim: Smoking is still one of the most important health problems of our country. The aim of our study was to identify the level of smoking habits of the teachers in the city of Bursa and find out their opinion about the law prohibiting smoking in closed areas.Material and Methods: A questionnaires containing 22 questions were distributed to all schools in Bursa. These questionnaires were answered by a total of 8291 teachers, composed of 3519 men (mean age 40.6 +/- 0.1) and 4772 women (mean age 34.9 +/- 0.1).Reults: Smoking ratio is 33.6% for male teachers and 25.4% for female teachers. The question "what do you think about the prohibition of smoking in closed areas in accordance with the law about Prevention and Control of Smoke Products Damage that just has came into force on 19 May 2008" was answered as a very necessary law by 75.8% and as an unnecessary law by 14.3% of the teachers.Conculation: As a result, the aspects of the smoker teachers were unfavorable compared to the non-smoker teachers. Consequently, we think that essential education and support should be given to our teachers, both to quit smoking and to being one of the foremost implementers of the law.